Understanding How Tuberculosis Bacteria Release Toxins
Toxin secretion and trafficking by Mycobacterium tuberculosis
This research explores how tuberculosis bacteria release a specific toxin to harm our cells, helping us understand how the infection spreads.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11141835 on NIH RePORTER |
What this research studies
Tuberculosis bacteria use a special toxin called CpnT to make host cells die, which helps the bacteria survive and spread. This toxin gets into our cells and depletes an important molecule, triggering a specific type of cell death. We know that mice resistant to this cell death pathway are better at fighting TB, suggesting this process is key to the disease. This work aims to uncover the exact ways this toxin is released and moves around inside our cells, which is crucial for the bacteria's survival and the progression of tuberculosis.
Who could benefit from this research
Good fit: This foundational research does not directly involve patient participation, but future studies building on this work might seek patients with tuberculosis.
Not a fit: Patients seeking immediate new treatments or direct clinical intervention will not find direct benefit from this basic science project.
Why it matters
Potential benefit: Understanding how tuberculosis bacteria use toxins to cause cell death could lead to new ways to fight the infection and develop more effective treatments.
How similar studies have performed: While the specific mechanisms of CpnT secretion are novel, the general concept of bacterial toxins influencing host cell death is well-established in microbiology.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Niederweis, Michael — University of Alabama at Birmingham
- Study coordinator: Niederweis, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.